帕金森病大鼠中缝背核5-羟色胺能神经元电活动的变化

本实验采用玻璃微电极细胞外记录法,观察了帕金森病(Parkinson’s disease,PD)大鼠中缝背核(dorsal raphe nucleus, DRN)5-羟色胺(5-hydroxytryptamine,5-HT)能神经元电活动的变化。在大鼠右侧中脑黑质致密部内微量注射6-羟多巴胺(6- hydroxydopamine,6-OHDA)制作PD模型。结果显示,对照组和PD组大鼠DRN中5-HT能神经元的放电频率分别是(1．76±0．11)spikes／s(n=24)和(2．43±0．17)spikes／(n=21),PD组大鼠的放电频率显著高于对照组(P<0．001)。在对照组大鼠,92％(22／24)的神经元呈规则放电,8％(2／24)为爆发式放电;在PD组大鼠,具有规则、不规则和爆发式放电的神经元比例分别为9％(2／21)、43％(9／21)和48％(10／21),爆发式放电的5-HT能神经元比例明显高于对照组(P<0．001)。在对照组大鼠,DRN内局部注射5-HT1A拮抗剂WAY-100635(3μg/200nL)显著增加5-HT能神经元的放电频率而不影响其放电形式(n=19,P<0．002);而WAY-100635不改变PD组大鼠5-HT能神经元的放电频率和放电形式(n=17,P>0．05)。结果提示,用6-OHDA损毁黑质致密部造成的PD模型大鼠中神经元5-HT1A受体功能失调,并且DRN参与PD的病理生理学机制。     

帕金森病大鼠中缝背核5-羟色胺能神经元放电频率和放电形式的变化

实验采用玻璃微电极细胞外记录法, 观察了帕金森病(Parkinson’s disease, PD)大鼠中缝背核(dorsal raphe nucleus, DRN)5- 羟色胺(5-hydroxytrypamine, 5-HT)能神经元电活动的变化。结果发现, 对照组和 PD 组大鼠 DRN 中 5-HT 能神经元的放电频率分别为(1.61 ±0.56) Hz 和(2.61 ±1.97) Hz, PD 组大鼠的放电频率显著高于对照组(P<0.05)。在对照组大鼠, 79% 的神经元呈现规则放电, 21% 为爆发式放电;在 PD 组大鼠,具有规则、不规则和爆发式放电的神经元比例分别为 36%、16% 和47%, 爆发式放电的 5-HT 能神经元比例明显高于对照组(P<0.05)。结果表明,帕金森病大鼠 DRN 中 5-HT 能神经元的放电频率增高, 且爆发式放电增多。     

5,7-双羟色胺损毁大鼠中缝背核后底丘脑核的神经活动增强

采用玻璃微电极在体细胞外记录法,观察了5,7-双羟色胺(5,7-dihydroxytryptamine,5,7-DHT)损毁大鼠中缝背核(dorsalraphenucleus,DRN)后,底丘脑核(subthalamicnucleus,STN)神经元电活动的变化。结果发现,对照组和DRN损毁组大鼠STN神经元的放电频率分别是(6.93±6.55)Hz和(11.27±9.31)Hz,DRN损毁组大鼠的放电频率显著高于对照组(P<0.01)。在对照组大鼠,13%的神经元呈现规则放电,46%为不规则放电,41%为爆发式放电;而在DRN损毁组大鼠,具有规则、不规则和爆发式放电的神经元比例分别为9%、14%和77%,爆发式放电的STN神经元比例明显高于对照组(P<0.01)。结果显示,DRN损毁后大鼠STN神经元的放电频率增高,爆发式放电增多,提示在正常大鼠DRN抑制STN神经元的活动。     

6-OHDA毁损黑质致密部对大鼠PPN和VL神经元放电活动的影响

目的：观察6-羟多巴胺单侧毁损黑质致密部多巴胺神经元后,脚桥核（PPN）和丘脑腹外侧核（VL）神经元自发放电活动的变化,探讨帕金森病（PD）的发病机制。方法：应用玻璃微电极细胞外记录法,观察对照组和PD组PPN和VL神经元的放电频率和放电形式的变化。结果：对照组和PD组大鼠PPN放电频率分别为（8．31±0．62）Hz和（10．70±0．85）Hz,PD组放电频率明显高于对照组（P〈0．05）。和对照组相比,PD组PPN的不规则和爆发式放电神经元构成比例明显增多（P〈0．01）,同时规则放电频率增加（P〈0．01）。对照组和PD组大鼠VL的放电频率分别为（6．25±0．54）Hz和（5．67±0．46）Hz,两组间没有显著性差异。VL神经元放电形式表现为不规则和爆发式放电,两组间构成比也没有明显差异,但PD组爆发式神经元放电频率明显降低（P〈0．01）。结论：PD状态下,PPN神经元活动增强,PPN可能参与了PD的病理生理过程,VL神经元放电可能受PPN神经元投射的调节。     

6-OHDA制备的帕金森病大鼠黑质神经元的超微结构改变

目的观察6-羟多巴胺(6-OHDA)单侧注射制备的帕金森病(PD)大鼠多巴胺(DA)能神经元的超微结构改变。方法单侧微量注射6-OHDA制备PD大鼠模型,用免疫荧光组织化学方法观察正常侧与6-OHDA注射侧黑质酪氨酸羟化酶(TH)阳性神经细胞及神经纤维的变化;并利用免疫电镜技术观察大鼠正常侧与注射侧黑质致密部DA能神经元的超微结构。结果免疫荧光法显示注射侧黑质致密部TH阳性细胞数和网状部TH阳性纤维面积与正常侧的百分比平均值分别为21.83%,23.19%。免疫电镜显示:TH免疫反应阳性产物表达于PD大鼠正常侧DA能神经元的高尔基复合体质膜面及胞质内,电子密度较高,注射侧很少见或几乎未见,且注射侧线粒体嵴有不同程度的溶解,呈空泡样变或髓样变,粗面内质网脱颗粒。结论6-OHDA可引起DA能神经元发生凋亡的超微结构改变。     

多巴胺D_2样受体直接调节正常及帕金森病模型大鼠苍白球神经元自发放电（英文）

苍白球是基底神经节间接环路的重要核团,在机体正常及病理状态下调节运动功能。前期研究工作显示苍白球接受来自黑质纹状体轴突侧支的多巴胺能纤维支配。苍白球表达多巴胺D1和D_2样受体。本研究旨在采用多管微电极细胞外电生理记录技术,探讨多巴胺D_2样受体对正常及帕金森病模型大鼠苍白球神经元自发放电的直接调控效应。结果显示,在正常大鼠上,微压力给予多巴胺D_2样受体激动剂quinpirole对苍白球神经元自发放电发挥不同的电生理效应。在所记录的61个苍白球神经元,quinpirole可使24个神经元的放电频率增加(62.7±11.2)%,而使另外16个神经元放电频率降低(37.5±2.9)%,联合给予D_2样受体阻断剂sulpride可阻断quinpirole对苍白球神经元自发放电的调控效应。在6-羟基多巴胺(6-hydroxydopamine,6-OHDA)帕金森病模型大鼠损毁侧所记录的47个苍白球神经元中,quinpirole可使其中25个神经元的放电频率增加(64.2±10.1)%,而使另外11个神经元放电频率降低(51.9±6.2)%。以上结果提示,多巴胺D_2样受体双向调节苍白球神经元的自发放电活动;在帕金森病状态下,多巴胺D_2样受体仍具有双向调节苍白球神经元兴奋性的效应。     

6-羟多巴胺纹状体内注射制作大鼠帕金森病模型的研究

目的 为拓宽6-OHDA损毁多巴胺能神经元所制备大鼠帕金森病模型的应用范围,采用多位点纹状体内注入6-OHDA的途径来制备模型。方法 研究用SD大鼠,两个针道内四点定位注射,每点注射3μg／μ16-OHDA3μl。结果 术后两周出现缓慢旋转,4周旋转行为达到7转／分并保持稳定;形态学染色可见损毁1周后注射侧黑质酪氨酸羟化酶免疫组化阳性细胞减少20％,2周后减少38％,3～4周减少70％以上,6周后损伤趋缓。高效液相-电化学法活体检测纹状体内多巴胺的代谢产物3、4-二羟基苯乙酸(DOPAC)和高香草酸(HVA),发现注射侧和非注射侧相比含量分别下降98．33％和96．05％;组织匀浆检测损毁侧黑质多巴胺含量下降了73％以上,3、4-二羟基苯乙酸(DOPAC)含量下降60％。结论 纹状体内注射6-OHDA能够制备帕金森病大鼠模型。     

5,7-双羟色胺侧脑室注射对大鼠内侧前额叶皮层神经元兴奋性的影响

本研究采用在体细胞外记录的方法,探讨了双侧侧脑室注射5,7-双羟色胺(5,7-dihydroxytryptamine,5,7-DHT)损毁大鼠脑内5-羟色胺(5-hydroxytryptamine,5-HT)神经元后,内侧前额叶皮层(medial prefrontal cortex,m PFC)锥体和中间神经元兴奋性的变化。实验结果显示:5,7-DHT注射到双侧侧脑室后第2周,m PFC和中缝背核内的5-HT水平较正常组显著下降。m PFC的锥体神经元的放电频率与正常组相比明显升高,爆发式放电显著增多,而中间神经元的平均放电频率显著降低,放电形式趋向不规则活动。结果提示5-HT能递质系统对m PFC神经元活动具有重要的调节作用。     

大鼠脑实质内远位触液神经元中5-HT1A受体的分布及其在神经病理性痛中的表达

本文旨在探讨大鼠脑实质内远位触液神经元中5-HT1A受体的分布及其在神经病理性痛中的作用.慢性结扎损伤坐骨神经建立大鼠神经病理性痛模型,分别以缩足潜伏期(paw withdrawal latency,PWL)和缩足阈值(paw withdrawal threshold,PWT)对大鼠热痛敏和机械触诱发痛反应进行评分,以可靠CB-HRP(cholera toxin subunit B with horseradish peroxidase)法追踪标记脑实质内远位触液神经元,用CB-HRP/5-HT1A受体免疫组织化学双重标记技术定位、鉴别5-HT1A受体在远位触液神经元中的表达,并计数分析5-HT1A受体分布和表达变化与痛行为表现之间的关系.结果表明,在神经病理性痛第1、3、A7、14天,大鼠的PWL分别为19.37±2.74、12.04±1.77、8.74±1.15、12.31±1.94,PWT分别为18.58±3.62、13.05±1.81、6.66±1.43、1 1.55±2.01.CB-HRP标记细胞出现的位置和数量恒定.每只动物CB-HRP/5-HT1A受体双重标记的细胞数量分别为276.14±36.00、161.72±28.41、108.64±6.8l、139.76±44.64,分别占该动物CB-HRP标记细胞总数的95%、60%、40%和55%.与对照组相比,神经病理性痛大鼠PWL、PWT及CB.HRP/5-HT1A受体双标细胞数均有显著性差异(P<0.01).结果提示,大鼠脑实质的特定部位恒定存在远位触液神经元,该类神经元大多含有5-HT1A受体,该受体的表达与神经病理性痛行为表现之间呈负相关关系.     

大鼠下丘脑LHA-PVN nesfatin-1神经通路构成及对胃运动的影响

目的:阐述LHA和PVN间nesfatin-1神经通路的构成,探讨PVN nesfatin-1对胃收缩幅度及频率的影响及潜在机制。方法:采用荧光金逆行追踪结合荧光免疫组化技术,观察LHA-PVN间nesfatin-1神经通路构成;采用细胞外放电记录,观察nesfatin-1对GD放点活动的影响;通过在体胃运动技术,观察nesfatin-1对清醒自由活动大鼠胃收缩幅度和频率的影响。结果:Nesfatin-1能够抑制GD-E神经元放电(1.97±0.12 Hz vs.1.15±0.07 Hz)促进GD-I神经元放电(1.74±0.10 Hz vs.3.04±0.18 Hz),H4928能够部分阻断nesfatin-1对GD神经元(GD-E:1.38±0.08 Hz,P0.05 vs.nesfatin-1;GD-I:2.49±0.15 Hz,P0.05 vs.nesfatin-1)的影响;PVN内微量注射nesfatin-1能够抑制大鼠胃运动,呈量效依赖关系;LHA和PVN间有nesfatin-1神经纤维联系;电刺激LHA后,GD神经元放电频率增加(GD-E:2.06±0.12 Hz vs.4.23±0.21 Hz,GD-I:1.61±0.09 Hz vs.4.83±0.25 Hz),预先向PVN注射抗NUCB2/nesfatin-1抗体后,GD-E神经元放电频率减弱(4.91±0.25 Hz vs.4.23±0.21 Hz),而GD-I神经元放电频率增强(4.15±0.18 Hz vs.4.83±0.25)。结论:PVN内nesfatin-1可调控大鼠GD神经元放电活动及胃运动,该效应受LHA调控。     

Unilateral lesion of the nigrostriatal pathway decreases the response of GABA interneurons in the dorsal raphe nucleus to 5-HT1A receptor stimulation in the rat

This study examined the firing rate and pattern of electrophysiologically and chemically identified GABA interneurons in the dorsal raphe nucleus (DRN), and role of 5-HT_1A receptor agonist 8-OH-DPAT and the medial prefrontal cortex (mPFC) in the firing activity in rats with 6-hydroxydopamine lesions of the substantia nigra pars compacta (SNc). The interneurons in rats with lesions of the SNc showed a more burst-firing, while having no change in the firing rate; the mPFC and combined mPFC and SNc lesions in rats decreased the firing rate of the interneurons and firing pattern shifted towards a more burst-firing compared to rats with sham lesions of the SNc, respectively. In rats with sham lesions of the SNc, administration of 8-OH-DPAT (1–243 μg/kg, i.v.) produced excitatory–inhibitory, excitatory and inhibitory effects in the firing rate of individual interneurons. However, when these effects were averaged over the group, 8-OH-DPAT had no significant effect on firing rate. In rats with lesions of the SNc, mPFC and the paired lesions, 8-OH-DPAT, at the same doses, inhibited all interneurons tested, respectively. Cumulative doses producing inhibition in rats with the paired lesions were higher than that of rats with lesions of the mPFC. In contrast to rats with sham lesions of the SNc, SNc lesion reduced expression of 5-HT_1A receptor on parvalbumin positive neurons in the DRN, a subpopulation of GABA interneurons. Our results indicate that the SNc and mPFC regulate the firing activity of GABA interneurons in the DRN. Furthermore, response of likely GABA interneurons to systemic administration of 8-OH-DPAT is altered by lesion of the SNc and mPFC.     

Unilateral lesion of the nigrostriatal pathway decreases the response of GABA interneurons in the dorsal raphe nucleus to 5-HT1A receptor stimulation in the rat

This study examined the firing rate and pattern of electrophysiologically and chemically identified GABA interneurons in the dorsal raphe nucleus (DRN), and role of 5-HT_1A receptor agonist 8-OH-DPAT and the medial prefrontal cortex (mPFC) in the firing activity in rats with 6-hydroxydopamine lesions of the substantia nigra pars compacta (SNc). The interneurons in rats with lesions of the SNc showed a more burst-firing, while having no change in the firing rate; the mPFC and combined mPFC and SNc lesions in rats decreased the firing rate of the interneurons and firing pattern shifted towards a more burst-firing compared to rats with sham lesions of the SNc, respectively. In rats with sham lesions of the SNc, administration of 8-OH-DPAT (1–243 μg/kg, i.v.) produced excitatory–inhibitory, excitatory and inhibitory effects in the firing rate of individual interneurons. However, when these effects were averaged over the group, 8-OH-DPAT had no significant effect on firing rate. In rats with lesions of the SNc, mPFC and the paired lesions, 8-OH-DPAT, at the same doses, inhibited all interneurons tested, respectively. Cumulative doses producing inhibition in rats with the paired lesions were higher than that of rats with lesions of the mPFC. In contrast to rats with sham lesions of the SNc, SNc lesion reduced expression of 5-HT_1A receptor on parvalbumin positive neurons in the DRN, a subpopulation of GABA interneurons. Our results indicate that the SNc and mPFC regulate the firing activity of GABA interneurons in the DRN. Furthermore, response of likely GABA interneurons to systemic administration of 8-OH-DPAT is altered by lesion of the SNc and mPFC.     

Effects of chronic, systemic treatment with the dopamine receptor agonist R-apomorphine in partially lesioned rat model of Parkinson's disease: an electrophysiological study of substantia nigra dopamine neurons

Previous studies have suggested that R-apomorphine (R-APO), a non-selective dopamine (DA) receptor agonist, has neuroprotective effects in the experimental models of Parkinson's disease (PD). In this study, we investigated the effects of chronic, systemic treatment with R-APO in the firing activity of substantia nigra pars compacta (SNc) DA neurons in 6-hydroxydopamine (6-OHDA) partially lesioned rats. In the 6-OHDA-lesioned rats treated with vehicle, injection of 6-OHDA (20.1 microg) into the striatum produced a partial lesion causing 41% loss of tyrosine hydroxylase-immunoreactive (TH-ir) neurons in the SNc. In the partially lesioned rats, chronic, systemic treatment of R-APO (10 mg/kg/day, s.c., 11 days) attenuated loss of TH-ir neurons in the SNc. The partial lesion of the nigrostriatal pathway and R-APO treatment did not change the firing rate and firing pattern of DA neurons in the SNc of rats. In contrast, the R-APO treatment increased the number of spontaneously active DA neurons of the SNc in the partially lesioned rats, while the lesion decreased the number of spontaneously active DA neurons. In addition, the chronic R-APO treatment decreased the responsiveness of the DA neurons to intravenously administrated R-APO in the partially lesioned rats. These results indicate that chronic, systemic R-APO treatment has the neuroprotective effect, and reverses the decrease in the number of spontaneously active DA neurons in the SNc whereas the treatment induces a reduction in the sensitivity of DA receptors in the SNc to R-APO stimulation in this model.     

Unilateral lesion of the nigrostriatal pathway decreases the response of fast-spiking interneurons in the medial prefrontal cortex to 5-HT1A receptor agonist and expression of the receptor in parvalbumin-positive neurons in the rat

5-Hydroxytryptamine_1A (5-HT_1A) receptors are expressed in the prefrontal cortical interneurons. Among these interneurons, calcium-binding protein parvalbumin (PV)-positive fast spiking (FS) interneurons play an important role in regulatory function of the prefrontal cortex. In the present study, the response of medial prefrontal cortex (mPFC) FS interneurons to the selective 5-HT_1A receptor agonist 8-OH-DPAT and change in expression of 5-HT_1A receptor on PV-positive neurons were examined in rats with 6-hydroxydopamine (6-OHDA) lesions of the substantia nigra pars compacta (SNc) by using extracellular recording and double-labeling immunofluorescence histochemistry. Systemic administration of 8-OH-DPAT (1-243 μg/kg, i.v.) dose-dependently inhibited the mean firing rate of the FS interneurons in sham-operated and the lesioned rats, respectively. The cumulative doses producing inhibition in the lesioned rats (243 μg/kg) was significantly higher than that of sham-operated rats (27 μg/kg). Furthermore, the local application of 8-OH-DPAT (0.01 μg) in the mPFC inhibited the FS interneurons in sham-operated rats, while having no effect on firing rate of the FS interneurons in the lesioned rats. In contrast to sham-operated rats, the lesion of the SNc in rats did not cause the change of PV-positive neurons in the prelimbic prefrontal cortex, a subregion of the mPFC, whereas the lesion of the SNc markedly reduced in percentage of PV-positive neurons expressing 5-HT_1A receptors. Our results indicate that degeneration of the nigrostriatal pathway results in the decreased response of FS interneurons in the mPFC to 5-HT_1A receptor stimulation, which attributes to down-regulation of 5-HT_1A receptor expression in these interneurons.     

Serotonin 5-HT receptor blockade enhances Ca(2+)/calmodulin-dependent protein kinase II function and membrane expression of AMPA receptor subunits in the rat hippocampus: implications for memory formation

Stimulation of hippocampal 5-HT(1A) receptors impairs memory retention. The highly selective 5-HT(1A) antagonist, WAY-100635, prevents the cognitive deficits induced not only by 5-HT(1A) stimulation but also by cholinergic or NMDA receptor blockade. On this basis, the effects of WAY-100635 on molecular events associated with memory storage were explored. In rat hippocampus, WAY-100635 produced a rapid increase in phosphorylated Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) and in Ca(2+)-independent CaMKII and protein kinase A (PKA) enzyme activity. This increase was followed a few hours later by an enhanced membrane expression of AMPA receptor subunits, especially of the GluR1 subunit phosphorylated at the CaMKII site, pGluR1(Ser831). The same qualitative effects were found with the weaker 5-HT(1A) antagonist NAN-190. The effects of both antagonists were no longer apparent in rats with a previous 5-HT depletion induced by the tryptophan hydroxylase inhibitor p-chlorophenylalanine (PCPA), suggesting that 5-HT(1A) receptor blockade removes the tonic inhibition of 5-HT through 5-HT(1A) receptor stimulation on excitatory hippocampal neurons, with the consequent increase in PKA activity. In addition, administration of WAY-100635 potentiated the learning-specific increase in the hippocampus of phospho-CaMKII, Ca(2+)-independent CaMKII activity, as well as the phosphorylation of either the CaMKII or the PKA site on the AMPA receptor GluR1 subunit. This study suggests that blockade of hippocampal 5-HT(1A) receptors favours molecular events critically involved in memory formation, and provides an in vivo molecular basis for the proposed utility of 5-HT(1A) receptor antagonists in the treatment of cognitive disorders.     

WAY-100635 antagonist-induced plasticity of 5-HT receptors: regulatory differences between a stable cell line and an in vivo native system

We present evidence that the 5-hydroxytryptamine(1A) (5-HT(1A)) receptor antagonist, N-{2-[4-(2-methoxyphenyl)-1-piperazinyl]-ethyl}-N-(2-pyridinyl)cyclohexanecarboxamide (WAY-100635), can induce receptor internalization in a human (h)5-HT(1A) receptor Chinese hamster ovary (CHO-K1) cell system. Exposure of h5-HT(1A) CHO cells to WAY-100635 decreased the cell-surface h5-HT(1A) receptor density in a way that was both time (24-72 h) and concentration (1-100 nm) dependent.[(3)H]WAY-100635 and [(3)H]8-hydroxy-dipropylaminotetralin ([(3)H]8-OH-DPAT) saturation analyses demonstrated a significant reduction (50-60%) in total h5-HT(1A) receptor number in the WAY-100635-treated (100 nm; 72 h) compared with control cells. In WAY-100635-treated cells, the 8-OH-DPAT-mediated inhibition of forskolin (FSK)-stimulated cAMP accumulation was right-shifted and the maximal inhibitory response of 8-OH-DPAT was impaired compared with control cells. Similar results were obtained for 8-OH-DPAT-mediated Ca(2+) mobilization after WAY-100635 treatment. h5-HT(1A) receptors labeled with [(3)H]WAY-100635, as well as [(3)H]4-(2'-Methoxy)-phenyl-1-[2'-(N-2'-pyridinyl)-p-fluorobenzamido]ethyl-piperazine (MPPF), exhibited a time-dependent rate of cellular internalization that was blocked by endocytotic suppressors and was pertussis-toxin insensitive. In contrast, quantitative autoradiographic studies demonstrated that chronic treatment of rats with WAY-100635 for two weeks produced a region-specific increase in the 5-HT(1A) receptor density. In conclusion, prolonged exposure of an h5-HT(1A) cell-based system to the 5-HT(1A) antagonist, WAY-100635, induced a paradoxical internalization of cell surface receptor resulting in depressed functional activity. This suggests that an antagonist can influence 5-HT(1A) receptor recycling in vitro differently to in vivo regulatory conditions.     

Activation of 5-hydroxytryptamine-1A receptors suppresses cardiovascular responses evoked from the paraventricular nucleus

Activation of central 5-hydroxytryptamine-1A (5-HT(1A)) receptors powerfully inhibits stress-evoked cardiovascular responses mediated by the dorsomedial hypothalamus (DMH), as well as responses evoked by direct activation of neurons within the DMH. The hypothalamic paraventricular nucleus (PVN) also has a crucial role in cardiovascular regulation and is believed to regulate heart rate and renal sympathetic activity via pathways that are independent of the DMH. In this study, we determined whether cardiovascular responses evoked from the PVN are also modulated by activation of central 5-HT(1A) receptors. In anesthetized rats, the increases in heart rate and renal sympathetic nerve activity evoked by bicuculline injection into the PVN were greatly reduced (by 54% and 61%, respectively) by intravenous administration of (±)-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), an agonist of 5-HT(1A) receptors, but were then completely restored by subsequent administration of WAY-100635, a selective antagonist of 5-HT(1A) receptors. Microinjection of 8-OH-DPAT directly into the PVN did not significantly affect the responses to bicuculline injection into the PVN, nor did systemic administration of WAY-100635 alone. In control experiments, a large renal sympathoexcitatory response was evoked from both the PVN and DMH but not from the intermediate region in between; thus the evoked responses from the PVN were not due to activation of neurons in the DMH. The results indicate that activation of central 5-HT(1A) receptors located outside the PVN powerfully inhibits the tachycardia and renal sympathoexcitation evoked by stimulation of neurons in the PVN.     

Presynaptic 5-HT1A receptors in immunomodulation

It is shown that a selective agonist of 5-HT1A receptors 8-OH-DPAT in a low dose (0.1 mg/kg), which is known to affect mainly the presynaptic 5-HT1A receptors increased the immune response at the peak of reactions (the forth or fifth day after immunization with sheep red blood cells - SRBC) in CBA mice and Wistar rats. Treatment of the animals with the drug 15 min prior to antigen injection raised the number of plaque-forming cells (lgM-PFC) and rosette-forming cells (RFC) in the spleen. The preliminary blockade of 5-HT1A receptor with a selective antagonist of 5-HT1A receptors WAY-100635 (0.1 mg/kg) prevented the immunostimulating effect of 5-HT 1A receptors agonist 8-OH-DPAT, whereas WAY-100635 administration alone in the same dose didn't change the immune response. Activation of 5-HT1A receptors under conditions of electrical lesion of 5-HTergic neurons of the nucleus raphe was unable to enhance the immune reactions, as it did in sham-operated rats. The data obtained indicate that the somatodendric 5-HT1A autoreceptors are involved in immunomodulation.